The BAG5 Knockout UM-UC-3 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the UM-UC-3 human bladder cancer cell line, designed to disrupt the BAG5 gene. BAG5 encodes a co-chaperone that inhibits parkin-mediated mitophagy and modulates Hsp70/Hsc70 chaperone activity, promoting cell survival under stress. This polyclonal population offers a heterogeneous gene-edited pool ideal for studying BAG5 function without clonal selection biases.
The UM-UC-3 cell line, derived from a grade II transitional cell carcinoma of the urinary bladder of a male patient, serves as an invasive bladder cancer model with documented metastatic potential. This cell line is widely used to study bladder cancer pathogenesis, invasion, and response to chemotherapeutic agents. As a representative system for intermediate-grade urothelial carcinoma, UM-UC-3 cells retain key signaling features relevant to tumor progression and drug resistance, making them a pertinent host for BAG5 knockout studies.
At the molecular level, BAG5 functions as a co-chaperone that directly interacts with Hsp70 family members HSPA8 and HSPA1A, and with PARK2 (parkin). BAG5 inhibits parkin E3 ligase activity, preventing parkin recruitment to depolarized mitochondria and blocking mitophagy initiation. This impairs mitophagy, resulting in accumulation of damaged mitochondria and reduced recruitment of LC3 and p62. Consequently, BAG5-mediated suppression of mitophagy enhances cell survival via activation of ERK1/2 signaling and modulation of Bcl-2 family proteins. Upstream regulators such as HSF1 and cellular stressors (oxidative stress, proteasome inhibition, ER stress) upregulate BAG5 expression to coordinate stress-adaptive responses.
In the context of UM-UC-3 bladder carcinoma cells, BAG5 knockout is expected to derepress parkin-mediated mitophagy, leading to increased clearance of dysfunctional mitochondria and potential sensitization to apoptotic stimuli. This genetic perturbation may reduce the chemoresistance often associated with advanced bladder cancer, as BAG5 upregulation has been linked to cisplatin resistance. Moreover, UM-UC-3 BAG5 knockout cells can be employed to investigate the interplay between BAG5 and MAPK/ERK signaling, providing insight into mechanisms that drive bladder cancer progression and drug sensitivity. The knockout model thus enables dissection of BAG5??s contributions to the balance between mitochondrial quality control and cell survival signaling in a tumor-relevant background.
This polyclonal knockout cell population is well-suited for a range of investigative assays. Researchers can employ Western blotting and RT-qPCR for knockout validation at the protein and mRNA levels, immunofluorescence to monitor parkin translocation to mitochondria, and flow cytometry (Annexin V) to quantify apoptosis. Mitophagy flux can be assessed using the mt-Keima assay, while co-immunoprecipitation experiments verify BAG5?CHsp70 interactions. Functional assays such as Transwell migration/invasion and cisplatin sensitivity (MTT assay) enable exploration of the metastatic and chemoresistant phenotypes. Applications extend to mechanistic studies of mitophagy in cancer, parkin regulation in neurodegeneration models, and drug discovery screening for Parkinson??s disease. For additional information or technical inquiries, please contact Ascent Research.
